Predictor at ART initiation
|
HR, 95% CI
|
P value
|
Model 1 adjusted HR, 95% CI
|
P value
|
Model 2 Adjusted HR, 95% CI
|
P value
|
---|
Age (years)
|
1.04 (0.90 − 1.21)
|
0.57
| | | | |
BMI (kg/m2)
|
0.94 (0.78–1.14)
|
0.56
| | | | |
Karnofsky Performance Scale
| | | | | | |
Minor symptoms (90)
|
Reference
| | | | | |
Moderate symptoms (80)
|
1.11 (0.11–10.63)
|
0.93
| | | | |
Unable to work (<80)
|
5.34 (0.55–51.38)
|
0.15
| | | | |
Current tuberculosis
|
3.01 (0.50–18.02)
|
0.23
| | | | |
WHO Stage
| | | | | | |
Stage I
|
Reference
| | | | | |
Stage II
|
0.66 (0.04–10.49)
|
0.77
| | | | |
Stage III
|
0.85 (0.08–9.34)
|
0.89
| | | | |
Stage IV
|
1.80 (0.11–28.77)
|
0.68
| | | | |
CD4 Cell count (cells/μL)
|
0.99 (0.97–1.01)
|
0.22
| | | | |
Log10 Plasma HIV-1 RNA (copies/mL)
|
3.00 (0.62–14.60)
|
0.17
| | | | |
Hemoglobin (g/dL)
|
0.59 (0.33–1.07)
|
0.08
|
0.51 (0.21–1.23)
|
0.13
|
0.41 (0.18–0.92)
|
0.03
|
Log10 Angiopoietin-1 (ng/mL)
|
0.25 (0.005–13.63)
|
0.50
| | | | |
Log10 Angiopoietin-2 (ng/mL)
|
18.85 (1.52–233.7)
|
0.02
|
41.31 (0.82–2,086)
|
0.06
|
75.06 (1.98–2,846)
|
0.02
|
Log10 ANG-2/ANG-1 ratio
|
19.99 (1.66–240.5)
|
0.02
| | | | |
Log10 s-ICAM (ng/mL)
|
10,062 (18.29–5,536,091)
|
0.004
|
355.8 (0.22–581,538)
|
0.12
| | |
Log10 E-selectin (ng/mL)
|
11.17 (0.18–696.4)
|
0.25
| | | | |
Log10 VCAM (ng/mL)
|
9.33 (0.14–644.0)
|
0.30
| | | | |
-
ART antiretroviral therapy, CI confidence interval, HR hazard ratio.